Our Goal: Developing smarter assessment solutions
Planning to Launch in 2017
Quadrant Biosciences is striving to address two of the most important and talked-about health issues facing parents and children today with key advancements in how they are evaluated: Concussion and Autism Spectrum Disorder.
This year in the US alone, 1.6 to 3.8 million athletes will experience a sports-related concussion. Despite increased public awareness, the standard tools used to evaluate and treat a concussion — self-reported symptoms and expert opinion — offer poor reliability and sensitivity. Consequently, many of these injuries are misdiagnosed, creating a heightened risk of serious secondary injuries if the athlete prematurely returns to play.
Understandably, physicians are frustrated with the absence of credible tools to objectively and quantitatively assess concussion injuries and the critical return-to-play decision; parents are worried about the health of their children and the unseen consequences of their injuries; and athletes are concerned about the extent of their injuries and unclear about the timeline for recovery.
Quadrant Biosciences is currently working on solutions to this problem on two fronts: functional assessment and epigenetic biomarkers.
Solution: The ClearEdge Assessment System
Introducing the ClearEdge Assessment System, a new standard of care that will integrate clinical best practices into a single system with cloud-based analytics. ClearEdge will offer clinicians a suite of testing applications that are:
Comprehensive — Designed to incorporate the clinical assessment of patient symptoms, physical performance and cognitive functions
Objective — Patient test results are quantitatively analyzed relative to prior performance and peer group statistics; this system uses advanced malingering-detection and effort-assessment techniques to limit possible test manipulation
Clinically reliable — The preliminary test-retest reliability assessment indicates that the system will be appropriate for clinical decision-making
Evolutionary — Academic research is translated to clinical practice; the inclusion of dual-task testing and effort assessment is a first in the industry
Cost Effective — The system’s low cost of acquisition and short testing interval (approximately 20 minutes) facilitate time and revenue efficiencies using existing CPT codes
Portable — The entire system fits in a briefcase; ClearEdge testing can occur almost anywhere
Solution: Concussion Biomarker in Saliva
There has been a big push by researchers to find a reliable biomarker test to objectively diagnose concussion, but thus far it has remained elusive. However, research we are conducting in cooperation with Penn State College of Medicine and SUNY Upstate Medical University, may change that. Focusing on epigenetic microRNA in the saliva, we have identified a novel and accurate biomarker for concussion in children. Among the significant findings of this research include:
Saliva a Rich Source - microRNA’s have been found in relative abundance in the saliva which, when coupled with their unique epigenetic properties, make them attractive biomarker candidates
Accurate Differentiation - Six microRNAs had parallel changes in CSF and saliva and could accurately separate concussion and control cases
Predictive of Symptom Duration - The study also showed compelling data that this biomarker may be a better predictor of symptom (headache, fatigue, difficulty concentrating, etc) duration than current standard concussion assessments.
Results of this research were presented at the 2017 Pediatric Academic Societies Meeting in San Francisco in May.
Autism Spectrum Disorder (ASD) is a medical condition that affects a person’s communication abilities and social skills, and often causes repetitive patterns of behavior and a narrow range of interests. The number of children diagnosed annually with ASD has increased significantly between 2000 and 2010, from one in 150 to one in 68.
Although there is no known cure for autism, early intervention with behavioral therapies (e.g., Applied Behavioral Techniques) has been shown to reduce the severity of symptoms and the disabling aspects of the condition. However, early intervention requires early diagnosis, and existing diagnostic tests lack the essential specificity to ASD to make them a useful tool for early screening.
Solution: Autism Screening Test
In cooperation with SUNY Upstate Medical Center and Penn State College of Medicine, Quadrant Biosciences has developed a unique test that facilitates the early diagnosis of ASD. Our autism screening test, which involves specific biomarkers, has been yielding impressive sensitivity and specificity numbers. This groundbreaking technology is expected to be commercially available in 2017.
Note: The products mentioned on this site are under development and have not been cleared by the FDA for distribution in the United States.